Novartis has reported a 41 percent drop in operating income to $150 million for its eyewear business unit, Alcon, in the second quarter, as a $119 million charge for impairment of intangible assets aggravated a drop in the core operating margin of 5.5 percentage points to 31.1 percent of sales. ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.